vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Spok Holdings, Inc (SPOK). Click either name above to swap in a different company.
Spok Holdings, Inc is the larger business by last-quarter revenue ($33.9M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). Spok Holdings, Inc runs the higher net margin — 8.7% vs -0.8%, a 9.5% gap on every dollar of revenue. On growth, Spok Holdings, Inc posted the faster year-over-year revenue change (-0.1% vs -25.7%). Spok Holdings, Inc produced more free cash flow last quarter ($10.1M vs $-15.8M). Over the past eight quarters, Spok Holdings, Inc's revenue compounded faster (-1.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Spok Holdings, Inc. is a global provider of critical communication solutions primarily serving the healthcare industry. It offers unified clinical communication platforms, secure messaging tools, alerting systems, and on-call scheduling software that help care teams coordinate efficiently, cut response times, and boost patient safety across medical facilities.
CTMX vs SPOK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $33.9M |
| Net Profit | $-154.0K | $2.9M |
| Gross Margin | — | 76.7% |
| Operating Margin | -6.9% | 11.6% |
| Net Margin | -0.8% | 8.7% |
| Revenue YoY | -25.7% | -0.1% |
| Net Profit YoY | 97.6% | -19.6% |
| EPS (diluted) | — | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $33.9M | ||
| Q3 25 | — | $33.9M | ||
| Q2 25 | $18.7M | $35.7M | ||
| Q1 25 | $50.9M | $36.3M | ||
| Q4 24 | $38.1M | $33.9M | ||
| Q3 24 | $33.4M | $34.9M | ||
| Q2 24 | $25.1M | $34.0M | ||
| Q1 24 | $41.5M | $34.9M |
| Q4 25 | — | $2.9M | ||
| Q3 25 | — | $3.2M | ||
| Q2 25 | $-154.0K | $4.6M | ||
| Q1 25 | $23.5M | $5.2M | ||
| Q4 24 | $18.9M | $3.6M | ||
| Q3 24 | $5.7M | $3.7M | ||
| Q2 24 | $-6.5M | $3.4M | ||
| Q1 24 | $13.8M | $4.2M |
| Q4 25 | — | 76.7% | ||
| Q3 25 | — | 78.3% | ||
| Q2 25 | — | 79.5% | ||
| Q1 25 | — | 80.1% | ||
| Q4 24 | — | 78.5% | ||
| Q3 24 | — | 79.5% | ||
| Q2 24 | — | 78.9% | ||
| Q1 24 | — | 79.5% |
| Q4 25 | — | 11.6% | ||
| Q3 25 | — | 12.9% | ||
| Q2 25 | -6.9% | 15.1% | ||
| Q1 25 | 44.4% | 16.6% | ||
| Q4 24 | 46.4% | 13.7% | ||
| Q3 24 | 12.3% | 14.2% | ||
| Q2 24 | -33.7% | 13.2% | ||
| Q1 24 | 28.1% | 14.0% |
| Q4 25 | — | 8.7% | ||
| Q3 25 | — | 9.5% | ||
| Q2 25 | -0.8% | 12.8% | ||
| Q1 25 | 46.2% | 14.3% | ||
| Q4 24 | 49.6% | 10.8% | ||
| Q3 24 | 17.2% | 10.5% | ||
| Q2 24 | -26.0% | 10.1% | ||
| Q1 24 | 33.3% | 12.1% |
| Q4 25 | — | $0.13 | ||
| Q3 25 | — | $0.15 | ||
| Q2 25 | — | $0.22 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | — | $0.18 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $25.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $146.4M |
| Total Assets | $175.1M | $206.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $25.3M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | $49.0M | $20.2M | ||
| Q1 25 | $47.6M | $19.9M | ||
| Q4 24 | $38.1M | $29.1M | ||
| Q3 24 | $40.6M | $27.8M | ||
| Q2 24 | $43.2M | $23.9M | ||
| Q1 24 | $36.2M | $23.3M |
| Q4 25 | — | $146.4M | ||
| Q3 25 | — | $148.7M | ||
| Q2 25 | $119.9M | $150.9M | ||
| Q1 25 | $25.0M | $151.7M | ||
| Q4 24 | $-456.0K | $154.7M | ||
| Q3 24 | $-23.5M | $156.3M | ||
| Q2 24 | $-31.2M | $158.2M | ||
| Q1 24 | $-31.7M | $160.2M |
| Q4 25 | — | $206.1M | ||
| Q3 25 | — | $209.7M | ||
| Q2 25 | $175.1M | $208.7M | ||
| Q1 25 | $98.5M | $204.5M | ||
| Q4 24 | $120.5M | $217.1M | ||
| Q3 24 | $139.0M | $216.8M | ||
| Q2 24 | $159.2M | $216.4M | ||
| Q1 24 | $184.7M | $215.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $11.5M |
| Free Cash FlowOCF − Capex | $-15.8M | $10.1M |
| FCF MarginFCF / Revenue | -84.6% | 29.9% |
| Capex IntensityCapex / Revenue | 0.1% | 4.1% |
| Cash ConversionOCF / Net Profit | — | 3.93× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $25.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $11.5M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | $-15.8M | $7.0M | ||
| Q1 25 | $-21.0M | $2.3M | ||
| Q4 24 | $-19.9M | $8.4M | ||
| Q3 24 | $-20.7M | $11.1M | ||
| Q2 24 | $-19.5M | $7.4M | ||
| Q1 24 | $-26.0M | $2.0M |
| Q4 25 | — | $10.1M | ||
| Q3 25 | — | $7.6M | ||
| Q2 25 | $-15.8M | $6.0M | ||
| Q1 25 | $-21.2M | $1.5M | ||
| Q4 24 | $-20.0M | $7.5M | ||
| Q3 24 | $-20.7M | $10.3M | ||
| Q2 24 | $-19.6M | $6.8M | ||
| Q1 24 | $-26.2M | $1.1M |
| Q4 25 | — | 29.9% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | -84.6% | 16.8% | ||
| Q1 25 | -41.6% | 4.2% | ||
| Q4 24 | -52.5% | 22.3% | ||
| Q3 24 | -62.1% | 29.4% | ||
| Q2 24 | -78.2% | 20.0% | ||
| Q1 24 | -63.1% | 3.2% |
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | 0.1% | 2.9% | ||
| Q1 25 | 0.2% | 2.1% | ||
| Q4 24 | 0.2% | 2.5% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 0.4% | 1.9% | ||
| Q1 24 | 0.3% | 2.5% |
| Q4 25 | — | 3.93× | ||
| Q3 25 | — | 2.54× | ||
| Q2 25 | — | 1.55× | ||
| Q1 25 | -0.89× | 0.43× | ||
| Q4 24 | -1.05× | 2.31× | ||
| Q3 24 | -3.61× | 3.03× | ||
| Q2 24 | — | 2.17× | ||
| Q1 24 | -1.89× | 0.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SPOK
| Paging | $16.8M | 50% |
| Software Operations | $16.0M | 47% |
| License | $1.2M | 4% |
